FGD2 Activators
FGD2 activators encompass a diverse range of chemical compounds that indirectly influence the functional activity of FGD2 by modulating various biological processes and signaling pathways in which this guanine exchange factor is involved. These compounds can alter the dynamics of the actin cytoskeleton, the balance of GTPase activities, or the broader signaling networks that intersect with the Rho family GTPases, thereby creating a context in which FGD2's GEF activity is more in demand. It is important to note that the effects of these chemicals are highly context-dependent and may vary based on cell type, the presence of other signaling molecules, and the overall physiological state of the cells.
Phorbol 12-myristate 13-acetate (PMA) is known for its potent ability to activate protein kinase C (PKC), a family of enzymes critical to several cellular functions like growth, differentiation, and survival. Upon activation, PKC can phosphorylate a diverse array of substrates, leading to varied cellular responses, including the reorganization of the actin cytoskeleton. PMA's influence on PKC and the subsequent actin dynamics could indirectly necessitate enhanced FGD2 GEF activity. As FGD2 catalyzes the exchange of GDP for GTP on Rho family GTPases, the heightened actin reorganization demands could drive the need for FGD2-mediated activation of these molecular switches, thereby facilitating the structural alterations necessary for cellular responses.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC), which can phosphorylate and activate a variety of downstream targets involved in cell growth, differentiation, and survival. PKC activation can lead to the actin cytoskeletal reorganization, where FGD2 functions as a GEF, facilitating the exchange of GDP for GTP on Rho family GTPases, enhancing their activity and leading to cytoskeletal changes. | ||||||
Lysophosphatidic Acid | 325465-93-8 | sc-201053 sc-201053A | 5 mg 25 mg | $98.00 $341.00 | 50 | |
LPA activates G protein-coupled receptors (GPCRs), leading to the activation of RhoA and subsequent actin cytoskeleton reorganization. FGD2 can be recruited to the plasma membrane in response to actin cytoskeleton changes, where it exerts its GEF activity for Cdc42, enhancing the signaling pathways that depend on this GTPase. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $121.00 $456.00 | 28 | |
Calpeptin is a calpain inhibitor that can indirectly affect cytoskeletal dynamics by preventing the proteolytic activity of calpains on cytoskeletal proteins. By stabilizing the cytoskeleton, calpeptin can enhance the activity of Rho family GTPases, potentially increasing the functional demand for FGD2's GEF activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing intracellular cAMP levels, which in turn can activate PKA. PKA can phosphorylate several downstream targets that may influence actin cytoskeleton dynamics, consequently increasing the functional activity of GTPases within this pathway, and thereby potentially enhancing the demand for FGD2's GEF activity. | ||||||
U-46619 | 56985-40-1 | sc-201242 sc-201242A | 1 mg 10 mg | $245.00 $1301.00 | 40 | |
U46619 is a thromboxane A2 mimic that activates thromboxane receptors, leading to the activation of RhoA and the Rho-associated protein kinase (ROCK) pathway, which is involved in actin cytoskeletal reorganization. Activation of this pathway may increase the functional demand for FGD2's GEF activity towards Rho GTPases. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide stabilizes actin filaments and promotes actin polymerization. As FGD2 is involved in the reorganization of the actin cytoskeleton by activating Rho GTPases, the stabilization of actin filaments by jasplakinolide can lead to increased demands for FGD2's GEF activity to maintain cytoskeletal dynamics. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC23766 inhibits Rac1 by blocking its binding to GEFs, but this inhibition can lead to compensatory cellular mechanisms that may increase the activity of other Rho GTPases, potentially increasing the functional demand for FGD2's activity as a GEF for other Rho family members. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a Cdc42 GTPase inhibitor that, by inhibiting Cdc42, can cause a compensatory | ||||||